Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search
  1. NCI-F Publications

Search
  1. Year Published:

Your search returned 23 results.
User Information
Export Records
  1. 1.   In vitro efficacy of immuno-chemotherapy with anti-EGFR human fab-taxol conjugate on A431 epidermoid carcinoma cells
  2. Wang, X.; Zhu, J.; Zhao, P.; Jiao, Y. G.; Xu, N.; Grabinski, T.; Liu, C.; Miranti, C. K.; Fu, T.; Cao, B. B.
  3. Cancer Biology & Therapy. 2007, Jun; 6(6): 980-986.
  1. 2.   Hypersusceptibility to cisplatin carcinogenicity in metallothionein-I/II double knockout mice: Production of hepatocellular carcinoma at clinically relevant doses
  2. Waalkes, M. P.; Liu, J.; Kasprzak, K. S.; Diwan, B. A.
  3. International Journal of Cancer. 2006, JUL 1; 119(1): 28-32.
  1. 3.   Role of GADD34 in modulation of cisplatin cytotoxicity
  2. Fishel, M. L.; Rabik, C. A.; Bleibel, W. K.; Li, X. M.; Moschel, R. C.; Dolan, M. E.
  3. Biochemical Pharmacology. 2006, JAN 12; 71(3): 239-247.
  1. 4.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 5.   International collaboration in drug discovery and development from natural sources
  2. Cragg, G. M.; Newman, D. J.
  3. Pure and Applied Chemistry. 2005, NOV; 77(11): 1923-1942.
  1. 6.   The role of IL-6 and STAT3 in inflammation and cancer
  2. Hodge, D. R.; Hurt, E. M.; Farrar, W. L.
  3. European Journal of Cancer. 2005, NOV; 41(16): 2502-2512.
  1. 7.   Low level, long-term inorganic arsenite exposure causes generalized resistance to apoptosis in cultured human keratinocytes: Potential role in skin co-carcinogenesis
  2. Pi, J. B.; He, Y. Y.; Bortner, C.; Huang, J. L.; Liu, J.; Zhou, T.; Qu, W.; North, S. L.; Kasprzak, K. S.; Diwan, B. A.; Chignell, C. F.; Waalkes, M. P.
  3. International Journal of Cancer. 2005, AUG 10; 116(1): 20-26.
  1. 8.   Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia
  2. Lemaire, M.; Momparler, L. F.; Bernstein, M. L.; Marquez, V. E.; Momparler, R. L.
  3. Anti-Cancer Drugs. 2005, MAR; 16(3): 301-308.
  1. 9.   Tumour stem cells and drug resistance
  2. Dean, M.; Fojo, T.; Bates, S.
  3. Nature Reviews Cancer. 2005 5(4): 275-284.
  1. 10.   Fluorinated 2-(4-amino-3-methylphenyl) benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells
  2. Brantley, E.; Trapani, V.; Alley, M. C.; Hose, C. D.; Bradshaw, T. D.; Stevens, M. F. G.; Sausville, E. A.; Stinson, S. F.
  3. Drug Metabolism and Disposition. 2004, DEC; 32(12): 1392-1401.
  1. 11.   Induction of stem cell factor/c-Kit/Slug signal transduction in multidrug-resistant malignant mesothelioma cells
  2. Catalano, A.; Rodilossi, S.; Rippo, M. R.; Caprari, P.; Procopio, A.
  3. Journal of Biological Chemistry. 2004, NOV 5; 279(45): 46706-46714.
  1. 12.   Brain tumor cell lines resistant to O-6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O-6 -alkylguanine-DNA alkyltransferase mutations
  2. Bacolod, M. D.; Johnson, S. P.; Pegg, A. E.; Dolan, M. E.; Moschel, R. C.; Bullock, N. S.; Fang, Q. M.; Colvin, O. M.; Modrich, P.; Bigner, D. D.; Friedman, H. S.
  3. Molecular Cancer Therapeutics. 2004, SEP; 3(9): 1127-1135.
  1. 13.   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models
  2. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D.
  3. Breast Cancer Research and Treatment. 2004, SEP; 87(1): 97-107.
  1. 14.   5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking
  2. Catalano, A.; Caprari, P.; Soddu, S.; Procopio, A.; Romano, M.
  3. Faseb Journal. 2004, SEP; 18(12): Published online only.
  1. 15.   Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XLAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
  2. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z. J.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R. X.; Fang, X. L.; Guo, R. B.; Zhang, M. C.; Lippman, M. E.; Yang, D. J.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2430-2440.
  1. 16.   Development of L-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity
  2. Song, Y. L.; Roller, P. P.; Long, Y. Q.
  3. Bioorganic & Medicinal Chemistry Letters. 2004 14(12): 3205-3208.
  1. 17.   Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
  2. Liu, J.; Li, C. X.; Qu, W.; Leslie, E.; Bonifant, C. L.; Buzard, G. S.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P.
  3. Molecular Cancer Therapeutics. 2004 3(6): 709-714.
  1. 19.   Regulating the p53 system through ubiquitination
  2. Yang, Y. L.; Li, C. C. H.; Weissman, A. M.
  3. Oncogene. 2004 23(11): 2096-2106.
  1. 20.   Potentiating effect of distant sites in non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain
  2. Long, Y. Q.; Guo, R. B.; Luo, J. H.; Yang, D. J.; Roller, P. P.
  3. Biochemical and Biophysical Research Communications. 2003 310(2): 334-340.
  1. 21.   Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event
  2. Geisbert, T. W.; Young, H. A.; Jahrling, P. B.; Davis, K. J.; Kagan, E.; Hensley, L. E.
  3. Journal of Infectious Diseases. 2003 188(11): 1618-1629.
  1. 22.   Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice
  2. Papadopoulou, M. V.; Ji, M.; Ji, X. H.; Bloomer, W. D.; Hollingshead, M. G.
  3. Cancer Chemotherapy and Pharmacology. 2002 50(6): 501-508.
  1. 23.   Characterization of the P53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations With the Growth-Inhibitory Potency of 123 Anticancer Agents
  2. Oconnor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S. J.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornace, A. J.; Kohn, K. W.
  3. Cancer Research. 1997 57(19): 4285-4300.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel